Polyrizon (NASDAQ:PLRZ) Shares Down 3.6% – What’s Next?

Shares of Polyrizon Ltd. (NASDAQ:PLRZ) were down 3.6% during trading on Monday. The stock traded as low as $9.13 and last traded at $9.26. 16,963 shares were traded during trading, a decline of 57% from the average daily volume of 39,804 shares. The stock had previously closed at $9.61.

Wall Street Analysts Forecast Growth

PLRZ has been the subject of a number of research analyst reports. Weiss Ratings upgraded shares of Polyrizon from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, September 18th. Wall Street Zen lowered Polyrizon from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Polyrizon Stock Down 5.4%

The business has a fifty day moving average of $11.10 and a 200 day moving average of $12.64.

Polyrizon (NASDAQ:PLRZ) last posted its earnings results on Monday, September 28th. The company reported ($0.40) earnings per share (EPS) for the quarter.

Polyrizon Company Profile

Polyrizon Ltd. is a biotechnology company developing nasal and respiratory-care products based on proprietary hydrogel technology. Its platform is designed to create a physical barrier on mucosal surfaces, potentially helping limit exposure to allergens, pollutants, and other airborne particles.

The company’s product candidates are focused primarily on intranasal applications, including solutions intended for allergic rhinitis and other upper-respiratory conditions. Polyrizon has described its technology as mucoadhesive, meaning that the hydrogels are designed to remain on nasal surfaces for an extended period while supporting localized protection.

Polyrizon is headquartered in Israel and is advancing its platform through product development and clinical or regulatory activities.